Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

Restrict the search for "JNJ-17203212" to a specific field?

Approximate Matches

1
Display Name

1
Related Substance Name

1
Standardized Name

1
Any Name

Exact Matches

1
Display Name

1
Related Substance Name

1
Standardized Name

1
Any Name

There is one exact (name or code) match for "JNJ-17203212"

JNJ-17203212

71JE0C439X

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Vanilloid receptor

Conditions:

JNJ-17203212 is an TRPV1 receptor antagonist. The drug exerts potent antinociceptive and antitussive actions. JNJ-17203212 is developing by Johnson & Johnson for the treatment of pain and cough. No development reported.

Showing 1 - 1 of 1 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

JNJ-17203212

71JE0C439X

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Vanilloid receptor

Conditions:

JNJ-17203212 is an TRPV1 receptor antagonist. The drug exerts potent antinociceptive and antitussive actions. JNJ-17203212 is developing by Johnson & Johnson for the treatment of pain and cough. No development reported.

Structure of JNJ-17203212

ACHIRAL

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1